January 17, 2023

expert reaction to NICE draft Quality Standard on treatment of depression in adults

The National Institute for Health and Care Excellence (NICE) have published a new draft quality standard on treatment of depression.

Prof Allan Young, Director, Centre for Affective Disorders, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London, said:

“It makes complete sense that the guidelines for treating depression in adults – which were published in June last year- are followed. These are not new recommendations for the way depression is treated but a document which describes key areas of care which NICE thinks can be improved on. Whether it can be delivered given the current state of the NHS is another question.”

‘Depression in adults, NICE quality standard, Draft for consultation’ was published by NICE at 00:01 UK time Tuesday 17 January.

https://www.nice.org.uk/guidance/indevelopment/gid-qs10165

Declared interests

Prof Allan Young: “Employed by King’s College London; Honorary Consultant SLaM (NHS UK)

Deputy Editor, BJPsych Open

Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Astrazenaca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, COMPASS, Sage

Consultant to Johnson & Johnson

Consultant to Livanova

Received honoraria for attending advisory boards and presenting talks at meetings organised by LivaNova.  Principal Investigator in the Restore-Life VNS registry study funded by LivaNova.

Principal Investigator on ESKETINTRD3004: “An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression.”

Principal Investigator on “The Effects of Psilocybin on Cognitive Function in Healthy Participants”

Principal Investigator on “The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)”

UK Chief Investigator for Novartis MDD study MIJ821A12201

Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK)

No shareholdings in pharmaceutical companies.”